Page last updated: 2024-08-16

trientine and methotrexate

trientine has been researched along with methotrexate in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Fukui, H; Ikenaka, Y; Kitade, M; Kuriyama, S; Namisaki, T; Noguchi, R; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H	1

Other Studies

2 other study(ies) available for trientine and methotrexate

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice. Oncology reports, 2005, Volume: 14, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Cell Line; Cell Line, Tumor; Cell Proliferation; Chelating Agents; Colorectal Neoplasms; Humans; Interleukin-8; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; RNA, Neoplasm; Treatment Outcome; Trientine; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2005

Article

Year

Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.

Current drug discovery technologies, 2004, Volume: 1, Issue:4

Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004

Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice.

Oncology reports, 2005, Volume: 14, Issue:1

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Cell Line; Cell Line, Tumor; Cell Proliferation; Chelating Agents; Colorectal Neoplasms; Humans; Interleukin-8; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; RNA, Neoplasm; Treatment Outcome; Trientine; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2005